Naloxone
Opioid Antagonist — ALIMENTARY TRACT AND METABOLISM
Also known as: (-)-Naloxone, evzio, l-naloxone, naloxone HCl, naloxone hydrobromide, naloxone hydrochloride, naloxone hydrochloride dihydrate, naloxone hydrochloride hydrate
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Naloxone is an ofp drug in the Opioid Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 1971. Its mechanism of action is classified as Opioid Antagonists. DrugCentral lists 16 molecular targets, including Oprm1, OPRM1 and Oprk1. Recorded indications include Opiate-Induced Respiratory Depression, Opioid dependence, Overdose of opiate and Pain.
- Approval status: ofp (first approved 1971 by the FDA).
- Drug class: Opioid Antagonist.
- Mechanism of action: Opioid Antagonists.
- Molecular targets: Oprm1, OPRM1, Oprk1 and Oprm1 (16 listed in DrugCentral).
- Indications: Opiate-Induced Respiratory Depression, Opioid dependence, Overdose of opiate, Pain and Poisoning by opiate analgesic drug and others.
- ATC code: A06AH04 (Peripheral opioid receptor antagonists).
- Molecular formula: C19H21NO4; molecular weight 327.38 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (6)
- Opiate-Induced Respiratory Depression
- Opioid dependence
- Overdose of opiate
- Pain
- Poisoning by opiate analgesic drug
- Prevention of opioid abuse
Contraindications (57)
- Acute abdominal pain
- Adrenal cortical hypofunction
- Alcohol intoxication
- Alcohol withdrawal delirium
- Asthenia
- Benign intracranial hypertension
- Benign prostatic hyperplasia
- Bradycardia
- Central nervous system depression
- Chronic disease of respiratory system
- Chronic hepatitis C
- Chronic obstructive lung disease
- Chronic type B viral hepatitis
- Coma
- Conduction disorder of the heart
- Congenital long QT syndrome
- Constipation
- Cor pulmonale
- Decreased respiratory function
- Dehydration
- Dependent drug abuse
- Disease of liver
- Disorder of biliary tract
- Disorder of gallbladder
- Drug-induced psychosis
- Dysfunction of sphincter of Oddi
- Exacerbation of asthma
- Hypercapnia
- Hypothyroidism
- Hypoxia
- + 27 more
Mechanism & targets
| Mechanism of action (MoA) | Opioid Antagonists |
|---|---|
| Established pharmacologic class | Opioid Antagonist |
Molecular targets (16)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Mu-type opioid receptor | Oprm1 | unknown | Kd 9.40 |
| Mu-type opioid receptor | OPRM1 | unknown | Ki 9.17 |
| Kappa-type opioid receptor | Oprk1 | unknown | Kd 9.00 |
| Mu-type opioid receptor | Oprm1 | antagonist | Ki 9.00 |
| Opioid receptor | Oprd1|Oprm1|Oprk1|Sigmar1 | unknown | Kd 9.00 |
| Mu-type opioid receptor | OPRM1 | antagonist | Ki 8.81 |
| Adenosine receptor A3 | ADORA3 | unknown | IC50 8.80 |
| Kappa-type opioid receptor | OPRK1 | unknown | Ki 8.50 |
| Kappa-type opioid receptor | OPRK1 | antagonist | Ki 8.50 |
| Mu-type opioid receptor | OPRM1 | unknown | IC50 8.30 |
| Kappa-type opioid receptor | Oprk1 | antagonist | IC50 8.30 |
| C-C chemokine receptor type 5 | Ccr5 | unknown | Kd 7.98 |
| Delta-type opioid receptor | Oprd1 | unknown | Kd 7.74 |
| Delta-type opioid receptor | Oprd1 | unknown | Kd 7.30 |
| Delta-type opioid receptor | OPRD1 | antagonist | Ki 7.27 |
| Cytochrome P450 2D6 | CYP2D6 | unknown | IC50 5.70 |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2017-11-09 | EMA | — | Mundipharma Corporation (Ireland) Limited | |
| 1971-04-13 | FDA | — | ADAPT |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
A06AH04 | ALIMENTARY TRACT AND METABOLISM › DRUGS FOR CONSTIPATION › DRUGS FOR CONSTIPATION › Peripheral opioid receptor antagonists |
N02AA53 | NERVOUS SYSTEM › ANALGESICS › OPIOIDS › Natural opium alkaloids |
N02AA55 | NERVOUS SYSTEM › ANALGESICS › OPIOIDS › Natural opium alkaloids |
N02AD51 | NERVOUS SYSTEM › ANALGESICS › OPIOIDS › Benzomorphan derivatives |
N02AX51 | NERVOUS SYSTEM › ANALGESICS › OPIOIDS › Other opioids |
V03AB15 | VARIOUS › ALL OTHER THERAPEUTIC PRODUCTS › ALL OTHER THERAPEUTIC PRODUCTS › Antidotes |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Toxicity to various agents | 847.4 |
| Overdose | 476.5 |
| Drug withdrawal syndrome | 362.0 |
| Drug withdrawal syndrome neonatal | 333.6 |
| Respiratory depression | 300.4 |
| Unresponsive to stimuli | 245.9 |
| Miosis | 202.6 |
| Drug abuse | 185.1 |
| Pulmonary oedema | 137.3 |
| Non-cardiogenic pulmonary oedema | 136.0 |
| Exposure during pregnancy | 132.0 |
| Depressed level of consciousness | 125.4 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Naloxone is on its molecule page.
| Molecular formula | C19H21NO4 |
|---|---|
| Molecular weight | 327.38 g/mol |
| CAS number | 465-65-6 |
| InChIKey | UZHSEJADLWPNLE-GRGSLBFTSA-N |
| PubChem CID | 5284596 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Naloxone used for?
DrugCentral lists the following indications for Naloxone: Opiate-Induced Respiratory Depression, Opioid dependence, Overdose of opiate, Pain, Poisoning by opiate analgesic drug and Prevention of opioid abuse.
How does Naloxone work?
Naloxone is classified as Opioid Antagonists; its molecular targets in DrugCentral include Oprm1, OPRM1, Oprk1 and Oprm1 (antagonist).
When was Naloxone first approved?
Naloxone was first approved by the FDA in 1971.
What drug class does Naloxone belong to?
Naloxone is in the Opioid Antagonist class.
What is the chemical formula of Naloxone?
Naloxone has the molecular formula C19H21NO4 and a molecular weight of 327.38 g/mol.
Browse: all drugs starting with N · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1878 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1718 — compound record and bioactivity
- PubChem CID 5284596 — chemical identifiers
- DrugBank DB01183 — drug record
- FDA UNII 36B82AMQ7N — substance identity
- DailyMed: FDA labels for Naloxone — current prescribing information (label search)
- UniProt P35372 (OPRM1) — target protein
- UniProt P0DMS8 (ADORA3) — target protein
- UniProt P41145 (OPRK1) — target protein
- UniProt P41143 (OPRD1) — target protein
- UniProt P10635 (CYP2D6) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.